The Role of Bisphosphonates in Preventing Skeletal Complications of Hormonal Therapy

Urologic Clinics of North America

Volumn 33, Issue 2, 2006, Pages 191-199

  Gilbert, Scott M ^a   McKiernan, James M ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; COLECALCIFEROL; ESTRADIOL; ESTROGEN; ETIDRONIC ACID; GONADORELIN AGONIST; LEUPRORELIN; NERIDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TRIPTORELIN; VITAMIN D; ZOLEDRONIC ACID; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ABDOMINAL PAIN; ACUTE TOXICITY; ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANDROPAUSE; ARTHRALGIA; BONE DENSITY; BONE LESION; BONE TURNOVER; BREAST CANCER; CALCIUM INTAKE; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CASTRATION; CELL ACTIVITY; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN THERAPY; FRAGILITY FRACTURE; HUMAN; KINESIOTHERAPY; LOW DRUG DOSE; METASTASIS; MORBIDITY; MULTIPLE MYELOMA; NAUSEA; ORCHIECTOMY; OSTEOCLAST; OSTEOPOROSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COUNSELING; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY OSTEOPOROSIS; STANDARD; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION; BONE DISEASE; CHEMICALLY INDUCED DISORDER; MALE; PROSTATE TUMOR;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; BONE DISEASES; DIPHOSPHONATES; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 33746464568     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2005.12.009     Document Type: Review

References (56)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics. CA Cancer J Clin 2005 55 (2005) 10-30
2. Jemel A., Murray T., Samuels A., et al. Cancer statistics. CA Cancer J Clin 2003 53 (2003) 5-26
3. Carlin B.I., and Andriole G.L. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 88 Suppl (2000) 2989-2994
4. Cooperberg M.R., Grossfeld G.D., Lubeck D.P., et al. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95 (2003) 981-989
5. Meng M.V., Grossfeld G.D., Sadetsky N., et al. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 60 Suppl 1 (2002) 7-12
6. Lindsay R., and Cosman F. Osteoporosis. In: Braunwald E., Fauci A.S., Kasper D.L., et al. (Eds). Harrison's principles of internal medicine. 15th edition (2001), McGraw-Hill, New York 2226-2237
7. Siddiqui N.A., and Shetty K.R. Osteoporosis in older men: discovering when and how to treat it. Geriatrics 54 (1994) 20-37
8. Kelepouris N., Harper K.D., and Gannon F.M. Severe osteoporosis in men. Ann Intern Med 123 (1995) 452-460
9. Mittan D., Lee S., Miller E., et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87 (2002) 3656-3661
10. Daniell H.W., Dunn S.R., Ferguson D.W., et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163 (2000) 181-186
11. Oefelein M.G., and Resnick M.I. The impact of osteoporosis in men treated for prostate cancer. Urol Clin North Am 31 (2004) 313-319
12. Diamond T.H., Higano C.S., Smith M.R., et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 100 (2004) 892-899
13. Kiratli B., Srinivas S., Perkash I., et al. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 57 (2001) 127-132
14. Wei J.T., Gross M., Jaffe C.A., et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 54 (1999) 607-611
15. Smith M.R., McGovern F.J., Fallon M.A., et al. Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer 91 (2001) 2238-2245
16. Conde F.A., Sarna L., Oka R.K., et al. Age, body mass index, and serum prostate-serum antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology 64 (2004) 335-340
17. Burger H., de Laet C.E., van Daele P.L., et al. Risk factors for increased bone loss in an elderly population: the Rotterdam study. Am J Epidemiol 147 (1998) 871-879
18. Nguyen T.V., Eisman J.A., Kelly P.J., et al. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol 144 (1996) 255-263
19. Melton III L.J., Atkinson E.J., O'Fallon W.M., et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 8 (1993) 1227-1233
20. Townsend S.F., Sanders W.H., Northway R.O., et al. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate adenocarcinoma. Cancer 79 (1997) 545-550
21. Daniell H.W. Osteoporosis after orchiectomy for prostate cancer. J Urol 157 (1997) 439-444
22. Melton L.J., Alothman K.I., Khosla S., et al. Fracture risk following bilateral orchiectomy. J Urol 169 (2003) 1747-1750
23. Hatano T., Oishi Y., Furuta A., et al. Incidence of bone fracture in patients receiving luteinizing hormone-releasing agonists for prostate cancer. BJU Int 86 (2000) 449-452
24. Oefelein M.G., Ricchuiti V., Conrad W., et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 166 (2001) 1724-1728
25. Diamond T.H., Bucci J., Kersley J.H., et al. Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. Urology 172 (2004) 529-532
26. Krupski T.L., Smith M.R., Lee W.C., et al. Natural history of bone complications in men with prostate cancer initiating androgen deprivation therapy. Cancer 101 (2004) 541-549
27. Shahinian V.B., Kuo Y.F., Freeman J.L., et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154-164
28. Stock H., Schneider A., and Strauss E. Osteoporosis: a disease in men. Clin Orthop 425 (2004) 143-151
29. Kiebzak G.M., Beinart G.A., Perser K., et al. Under-treatment of osteoporosis in men with hip fracture. Arch Intern Med 162 (2002) 2217-2222
30. Diamond T.H., Thornley S.W., Sekel R., et al. Hip fractures in elderly men: prognostic factors and outcomes. Med J 167 (1997) 412-415
31. De Laet C.E., and Pois H.A. Fractures in the elderly: epidemiology and demography. Best Pract Res Clin Endocrinol Metab 14 (2000) 171-179
32. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 285 (2001) 785-795
33. Oefelein M.G., Ricchiuti V., Conrad W., et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168 (2002) 1005-1007
34. Dawson-Hughes B., Harris S.S., Krall E.A., et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N Engl J Med 337 (1997) 670-676
35. Smith M.R., McGovern F.J., Zietman A.L., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345 (2001) 948-955
36. Smith M.R., Eastham J., Gleason D.M., et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169 (2003) 2008-2012
37. Vincent K.R., and Braith R.W. Resistance exercise and bone turnover in elderly men and women. Med Sci Sport Exerc 34 (2002) 17-23
38. Eriksson S., Eriksson A., Stege R., et al. Bone mineral density in patients with prostate cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 57 (1995) 97-99
39. Scherr D., Pitts W.R., and Vaughan E.D. Diethylstilbestrol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol 167 (2002) 535-538
40. Ockrim J.L., Lalani E.N., Laniado M.E., et al. Transdermal estradiol therapy for advanced prostate cancer: forward to the past?. J Urol 169 (2003) 1735-1737
41. Stepan J.J., lachman M., Zverina J., et al. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 69 (1989) 523-527
42. Russell R.G., Croucher P.I., and Rogers M.J. Bisphosphonates: pharmacology, mechanism of action and clinical use. Osteoporos Int 9 Suppl 2 (1999) S66-S80
43. Orwoll E., Ettinger M., Weiss S., et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 343 (2000) 604-610
44. Gonnelli S., Cepollaro C., Montagnani A., et al. Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int 73 (2003) 133-139
45. Filipponi P., Cristallini S., Policani G., et al. Paget's disease of bone: benefits of neridronate as a first treatment and in cases of relapse after clodronate. Bone 23 (1998) 543-548
46. O'Rourke N.P., McCloskey E.V., Rosini S., et al. Treatment of malignant hypercalcemia with aminohexane bisphosphonate (neridronate). Br J Cancer 69 (1994) 914-917
47. Morabito N., Gaudio A., Lasco A., et al. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer. J Bone Miner Res 19 (2004) 1766-1770
48. Magno C., Anastasi G., Morabito N., et al. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate. Eur Urol 47 (2005) 575-581
49. Hortobagyi G.N., Theriault R.L., Porter L., et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335 (1996) 1785-1791
50. Berenson J.R., Lichtenstein A., Porter L., et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334 (1996) 488-493
51. Ross J.R., Saunders Y., Edmonds P.M., et al. Systemic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 327 (2003) 469-475
52. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (2002) 1458-1468
53. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879-882
54. Diamond T., Campbell J., Bryant C., et al. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 83 (1998) 1561-1566
55. Diamond T.H., Winters J., Smith A., et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade. Cancer 92 (2001) 1444-1450
56. Tanvetyanon T. Physician practice of bone mineral density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer 103 (2005) 237-241